These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 30325755)

  • 21. Circulating tumor cells as promising novel biomarkers in solid cancers.
    Lianidou ES; Strati A; Markou A
    Crit Rev Clin Lab Sci; 2014 Jun; 51(3):160-71. PubMed ID: 24641350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of the combination of circulating tumor cells plus KRAS in patients with metastatic colorectal cancer treated with chemotherapy plus bevacizumab.
    Sastre J; Vidaurreta M; Gómez A; Rivera F; Massutí B; López MR; Abad A; Gallen M; Benavides M; Aranda E; Rubio ED;
    Clin Colorectal Cancer; 2013 Dec; 12(4):280-6. PubMed ID: 24012456
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in the Characterization of Circulating Tumor Cells in Metastatic Breast Cancer: Single Cell Analyses and Interactions, and Patient-Derived Models for Drug Testing.
    Kujur PK; Flores BCT; Ramalingam N; Chinen LTD; Jeffrey SS
    Adv Exp Med Biol; 2020; 1220():61-80. PubMed ID: 32304080
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating Tumor Cells (CTCs) Heterogeneity in Metastatic Breast Cancer: Different Approaches for Different Needs.
    Vismara M; Reduzzi C; Daidone MG; Cappelletti V
    Adv Exp Med Biol; 2020; 1220():81-91. PubMed ID: 32304081
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards a personalized breast cancer treatment approach guided by circulating tumor cell (CTC) characteristics.
    Onstenk W; Gratama JW; Foekens JA; Sleijfer S
    Cancer Treat Rev; 2013 Nov; 39(7):691-700. PubMed ID: 23683721
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Circulating tumor cells in bladder cancer: Emerging technologies and clinical implications foreseeing precision oncology.
    Azevedo R; Soares J; Peixoto A; Cotton S; Lima L; Santos LL; Ferreira JA
    Urol Oncol; 2018 May; 36(5):221-236. PubMed ID: 29530466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of the hormone receptor status of circulating tumor cell subpopulations based on epithelial-mesenchymal transition: a proof-of-principle study on the heterogeneity of circulating tumor cells.
    Guan X; Ma F; Liu S; Wu S; Xiao R; Yuan L; Sun X; Yi Z; Yang H; Xu B
    Oncotarget; 2016 Oct; 7(40):65993-66002. PubMed ID: 27602758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and Quantitation of Circulating Tumor Cells.
    Rawal S; Yang YP; Cote R; Agarwal A
    Annu Rev Anal Chem (Palo Alto Calif); 2017 Jun; 10(1):321-343. PubMed ID: 28301753
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of CTCs as Tumor Biomarkers.
    Lianidou ES; Markou A; Strati A
    Adv Exp Med Biol; 2015; 867():341-67. PubMed ID: 26530376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Potential of Circulating Tumor Cells in Personalized Management of Breast Cancer: A Systematic Review.
    Khatami F; Aghayan HR; Sanaei M; Heshmat R; Tavangar SM; Larijani B
    Acta Med Iran; 2017 Mar; 55(3):175-193. PubMed ID: 28282718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatic cancer circulating tumor cells: applications for personalized oncology.
    DiPardo BJ; Winograd P; Court CM; Tomlinson JS
    Expert Rev Mol Diagn; 2018 Sep; 18(9):809-820. PubMed ID: 30099926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer.
    Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K
    Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer.
    Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M
    Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diversity of assessing circulating tumor cells (CTCs) emphasizes need for standardization: a CTC Guide to design and report trials.
    Bünger S; Zimmermann M; Habermann JK
    Cancer Metastasis Rev; 2015 Sep; 34(3):527-45. PubMed ID: 26323491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic role of circulating tumor cells in colorectal cancer.
    Nanduri LK; Hissa B; Weitz J; Schölch S; Bork U
    Expert Rev Anticancer Ther; 2019 Dec; 19(12):1077-1088. PubMed ID: 31778322
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system.
    Andreopoulou E; Yang LY; Rangel KM; Reuben JM; Hsu L; Krishnamurthy S; Valero V; Fritsche HA; Cristofanilli M
    Int J Cancer; 2012 Apr; 130(7):1590-7. PubMed ID: 21469140
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
    Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
    World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients.
    Huebner H; Fasching PA; Gumbrecht W; Jud S; Rauh C; Matzas M; Paulicka P; Friedrich K; Lux MP; Volz B; Gass P; Häberle L; Meier-Stiegen F; Hartkopf A; Neubauer H; Almstedt K; Beckmann MW; Fehm TN; Ruebner M
    BMC Cancer; 2018 Feb; 18(1):204. PubMed ID: 29463222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer.
    Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K
    Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating tumor cells in colorectal cancer in the era of precision medicine.
    Hu M; Wang Z; Wu Z; Ding P; Pei R; Wang Q; Xing C
    J Mol Med (Berl); 2022 Feb; 100(2):197-213. PubMed ID: 34802071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.